Wealthy Indian American Woman with a $100 million net worth hails from Mumbai and has been recognized as influential by TIME.
Vertex Pharmaceuticals' CEO Reshma Kewalramani Achieves Milestones in Biotech Industry
Under the leadership of Reshma Kewalramani, Vertex Pharmaceuticals made history by securing FDA approval for the first CRISPR-based gene editing therapies to treat sickle cell disease and beta thalassemia. This significant achievement marked a turning point in the field of gene editing and has cemented Kewalramani's position as a global icon in the biotech industry.
Kewalramani, born in Mumbai, India, moved to the United States at the age of 11. She completed her medical training at Massachusetts General Hospital and Brigham and Women's Hospital, and later joined Vertex Pharmaceuticals in 2017 as Chief Medical Officer. In April 2020, she was appointed as the CEO and President of the company.
Vertex Pharmaceuticals, a major global biotech firm, reported robust financial performance in early 2025, with a Q1 revenue of $2.76 billion and strong growth prospects. Despite the company's strong business outlook and share price gains, Kewalramani's personal net worth remains in the low hundreds of millions, largely tied to her executive position and equity ownership in the company.
As of mid-2025, Kewalramani's net worth is estimated to be between $100 million and $103 million, reflecting her holdings including approximately 105,915 shares in Vertex Pharmaceuticals. She has earned roughly $53.6 million through stock sales since 2021.
In addition to her role at Vertex, Kewalramani holds directorship roles, including with Ginkgo Bioworks. She completed the General Management Program at Harvard Business School in 2015.
Kewalramani's accomplishments have not gone unnoticed. In 2024, her compensation package as CEO was valued at $21.5 million. In 2025, she was recognized on TIME magazine's list of the "100 Most Influential People."
Vertex Pharmaceuticals is also working on opioid-free pain medications, a promising development in the field of pain management. Kewalramani's leadership and vision continue to drive the company forward, making significant strides in the biotech industry.
The economic impact of Vertex Pharmaceuticals' success extends beyond the biotech industry, attracting financial investors and creating a ripple effect in the global market. This financial growth has been mirrored in Kewalramani's personal finances, with her net worth estimated to be between $100 million and $103 million, largely derived from her equity ownership in the company.
Involved in more than her role at Vertex, Kewalramani also holds directorship roles, such as with Ginkgo Bioworks, showcasing her commitment to the broader biotech and technology landscape.
Given her achievements and influence over the biotech and technology sectors, some analysts have begun to explore the potential impact of Kewalramani's growing influence on the rapidly evolving field of decentralized finance (Defi) in the economy.
